Revenue
2018
2019
2020
2021
2022
2023
2024
2025
OCULAR THERAPEUTIX, INC (OCUL)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.0M | $63.7M | $58.4M | $51.5M | $43.5M | $17.4M | $4.2M | $2.0M | $1.9M | $1.9M | $1.8M | $772,000 | — | $10,000 |
| Research & development | $197.1M | $127.6M | $61.1M | $53.5M | $50.1M | $28.7M | $41.1M | $36.9M | $30.9M | $27.1M | $26.6M | $18.9M | $10.5M | $11.5M |
| Operating expenses | — | — | — | — | — | — | — | — | — | — | $39.9M | $27.9M | $12.9M | $13.7M |
| Operating income | −$270.0M | −$171.8M | −$82.4M | −$78.7M | −$78.0M | −$62.8M | −$85.8M | −$59.1M | −$61.9M | −$43.3M | −$38.2M | −$27.1M | −$12.9M | −$13.7M |
| EBITDAderived | −$265.7M | −$168.0M | −$79.4M | −$76.5M | −$75.6M | −$60.1M | −$83.3M | −$56.8M | −$60.3M | −$42.4M | −$37.4M | −$26.5M | −$12.5M | −$13.3M |
| Net income | −$265.9M | −$193.5M | −$80.7M | −$71.0M | −$6.6M | −$155.6M | −$86.4M | −$60.0M | −$63.4M | −$44.7M | −$39.7M | −$28.6M | −$13.3M | −$14.1M |
| Basic EPSper diluted share | -$1.42 | -$1.22 | -$1.01 | -$0.92 | -$0.09 | -$2.56 | -$1.91 | -$1.57 | -$2.20 | -$1.80 | -$1.71 | -$2.69 | -$5.11 | -$5.60 |
| Diluted EPSper diluted share | -$1.42 | -$1.22 | -$1.02 | -$0.97 | -$0.98 | -$2.56 | -$1.91 | -$1.57 | -$2.20 | -$1.80 | -$1.71 | -$2.69 | -$5.11 | -$5.60 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 3, 2026Form 4 · 10b5-1 | Waheed NadiaChief Medical Officer | SellCommon Stock | 14.8K | $8.27 | $122.6K | 300.1K |
| May 26, 2026Form 4 · 10b5-1 | Dugel PravinSee Remarks | SellCommon Stock | 21.2K | $8.20 | $173.5K | 2.60M |
| May 26, 2026Form 4 · 10b5-1 | Kaiser PeterChief Development Officer | SellCommon Stock | 3.0K | $8.20 | $24.3K | 266.1K |
| May 26, 2026Form 4 · 10b5-1 | Heier Jeffrey S.Chief Scientific Officer | SellCommon Stock | 3.0K | $8.20 | $24.7K | 320.4K |
| May 26, 2026Form 4 · 10b5-1 | Nayak SanjayChief Strategy Officer | SellCommon Stock | 1.9K | $8.20 | $15.2K | 328.8K |